Adapthealth vs McKesson: why the prices moved differently

• ▼

  Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

  This is the single biggest new force behind AHCO's price drop this period.

• ▼

  Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

  Cash flow weakness and legal risk are new, concrete reasons investors are selling.

• ▲

  Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

  This is a major new strategic move that could support the stock by simplifying the company.

• ◆

  New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

  A new CFO is a new event that could affect how investors view the company's financial credibility.

Based on 9 stories →

• ▲

  Raised fiscal 2027 EPS guidance on broad-based growth McKesson lifted its full-year adjusted EPS guidance to $44.20–$45.00, implying 15–17% growth, after Q1 revenue rose 8% and adjusted EPS climbed 20%. Higher expected profits make the stock more attractive to investors.

  This is the core new event that directly raises profit expectations and pushes the stock up.

• ▲

  Oncology and GLP-1 distribution surge Oncology and multispecialty revenue jumped 33% to $14.2 billion, and GLP-1 distribution revenue reached $15 billion, up about 24% year over year. These fast-growing areas are becoming a bigger part of McKesson's business, supporting higher profits and a higher stock price.

  This explains the underlying demand strength that is driving the guidance raise and future growth.

• ▲

  CVS Health distribution deal extended through June 2032 McKesson signed an agreement in principle to extend its drug distribution partnership with CVS Health through June 2032, building on a 25-year relationship. The extension locks in a major customer, giving investors more confidence in steady future revenue.

  This is a new, concrete event that secures long-term demand and supports the stock.

• ▲

  Option Care Health acquisition for $1.4 billion stake McKesson agreed to invest $1.4 billion for a 49% stake in Option Care Health, a home infusion provider, as part of a $5.8 billion deal with CD&R. This expands McKesson's reach into home care, a growing area, and signals strategic investment that could add future earnings.

  This is a new M&A event that expands McKesson's business and is a key driver of recent stock movement.

Based on 7 stories →

• ▲

  Raised fiscal 2027 guidance on broad-based growth McKesson raised full-year adjusted EPS guidance to $44.20–$45.00, implying 13–15% growth, after first-quarter results beat expectations. Three of four segments posted double-digit growth, led by oncology and prescription technology. This directly lifts investor expectations for future profits, pushing the stock up.

  This is the core new positive event that answers why MCK is moving right now.

• ▲

  Oncology and GLP-1 distribution surge Oncology & Multispecialty revenue jumped 33% to $14.2 billion with operating profit up 41%, while GLP-1 distribution revenue reached $15 billion, up 24% year over year. These high-growth areas are becoming a bigger part of McKesson's business, supporting higher profits and a higher stock price.

  It explains the fundamental growth engine behind the raised guidance and investor optimism.

• ▲

  Acquisition of Precision Medicine Group for $2.25 billion McKesson agreed to buy Precision Medicine Group, a clinical research and biopharma services provider, for about $2.25 billion. The deal expands its higher-growth oncology and specialty services. While modest in size, it signals continued strategic investment that could add future earnings, supporting the stock.

  This is a new strategic move that investors are evaluating as a driver of future growth.

• ▼

  Branded drug price cuts and integration risks persist Price reductions by branded manufacturers cut North American Pharmaceutical revenue growth by about 3 percentage points and are expected to continue through fiscal 2027. Acquisition integration and unpredictable Prescription Technology Solutions performance also pose risks. These pressures can limit profit growth and weigh on the stock.

  It provides the necessary counterweight, showing real headwinds that could offset positive drivers.

Based on 6 stories →